RIPK1-IN-43
RIPK1-IN-43 is a triazolopyridine compound and also a RIPK1 inhibitor. RIPK1-IN-43 can be used in the research of diseases associated with abnormal RIPK1, such as multiple sclerosis, Parkinson's disease, non-alcoholic steatohepatitis, etc.
For research use only. We do not sell to patients.
- Formula: C22H17F4N9
- Molecular Weight:483.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
RIPK1 |
In Vitro
Chemical Information
-
Molecular Weight 483.42
-
Formula C22H17F4N9
-
SMILES
CC(F)(F)C(C1=CC(F)=CC(F)=C1)N(N=C2)N=C2C3=NC(C4=C(C)C5=NC(N)=NN5C=C4)=CN=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)